Trius to Present at the JMP Securities Healthcare Conference

Trius to Present at the JMP Securities Healthcare Conference
SAN DIEGO, July 8, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief
Executive Officer of Trius Therapeutics, will provide a corporate presentation
on Tuesday, July 9^th at 9:30 a.m. Eastern Time at the JMP Securities
Healthcare Conference at the St. Regis Hotel in New York.
A live webcast will be available through the Investor Relations page of the
Trius website at http://investor.triusrx.com/events.cfm. A webcast replay will
be available approximately two hours after the presentation and will be
archived for 30 days.
About Trius Therapeutics
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational drug, tedizolid
phosphate, is a novel antibiotic in Phase 3 clinical development for the
treatment of serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
Investigational New Drug (IND) enabling studies for its Gyrase-B development
candidate with potent activity against Gram-negative bacterial pathogens
including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter
and Pseudomonas.For more information, visit www.triusrx.com.
CONTACT: Public Relations Contact:
Laura Kempke/Stacey Holifield at MSLGROUP
trius@mslgroup.com
781-684-0770
Investor Relations Contact:
Stefan Loren at Westwicke Partners, LLC
sloren@westwicke.com
443-213-0507